Your browser doesn't support javascript.
loading
Mitochondrial Biomarkers and Metabolic Syndrome in Bipolar Disorder.
Zachos, Kassandra A; Choi, Jaehyoung; Godin, Ophelia; Chernega, Timofei; Kwak, Haejin Angela; Jung, Jae H; Aouizerate, Bruno; Aubin, Valérie; Bellivier, Frank; Belzeaux-R, Raoul; Courtet, Philippe; Dubertret, Caroline; Etain, Bruno; Haffen, Emmanuel; Lefrere A, Antoine; Llorca, Pierre-Michel; Olié, Emilie; Polosan, Mircea; Samalin, Ludovic; Schwan, Raymund; Roux, Paul; Barau, Caroline; Richard, Jean Romain; Tamouza, Ryad; Leboyer, Marion; Andreazza, Ana C.
Afiliação
  • Zachos KA; Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Mitochondrial Innovation Initiative, MITO2i, Toronto, ON, Canada.
  • Choi J; Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Mitochondrial Innovation Initiative, MITO2i, Toronto, ON, Canada.
  • Godin O; INSERM U955 IMRB, Translational Neuropsychiatry laboratory, AP-HP, Hôpital Henri Mondor, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Paris Est Créteil University (UPEC), ECNP Immuno-NeuroPsychiatry Network; Fondation FondaMental, Créteil, Franc
  • Chernega T; Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Kwak HA; Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Jung JH; Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Aouizerate B; Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens, Pôle de Psychiatrie Générale et Universitaire, Laboratoire NutriNeuro (UMR INRAE 1286), Université de Bordeaux, Bordeaux, France.
  • Aubin V; Fondation FondaMental, Créteil, France; Pôle de Psychiatrie, Centre Hospitalier Princesse Grace, Monaco.
  • Bellivier F; Fondation FondaMental, Créteil, France; Université Paris Cité, INSERM UMR-S1144, AP-HPm GH Saint-Louis-Bariboisière-Fernand Widal, Pôle Neurosciences, Paris Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris, France; AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, DMU Neurosciences
  • Belzeaux-R R; Fondation FondaMental, Créteil, France; Univ. Montpellier & Department of Psychiatry, CHU de Montpellier, France.
  • Courtet P; Fondation FondaMental, Créteil, France; IGF, Univ. Montpellier, CNRS, INSERM, Department of Emergency Psychiatry and Acute Care, CHU Montpellier, Montpellier, France.
  • Dubertret C; Fondation FondaMental, Créteil, France; AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, DMU ESPRIT, Service de Psychiatrie et Addictologie, Hôpital Louis Mourier, Colombes, France, Université de Paris, Inserm UMR1266, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
  • Etain B; Fondation FondaMental, Créteil, France; Université Paris Cité, INSERM UMR-S1144, AP-HPm GH Saint-Louis-Bariboisière-Fernand Widal, Pôle Neurosciences, Paris Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris, France; AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, DMU Neurosciences
  • Haffen E; Fondation FondaMental, Créteil, France; Université de Franche-Comté, UR 481 LINC, Service de Psychiatrie de l'Adulte, CIC-1431 INSERM, CHU de Besançon, F-2500, France.
  • Lefrere A A; Fondation FondaMental, Créteil, France; Pôle de Psychiatrie, Assistance Publique Hôpitaux de Marseille, Marseille, France, INT-UMR7289, CNRS Aix-Marseille Université, Marseille, France.
  • Llorca PM; Fondation FondaMental, Créteil, France; Department of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), Clermont-Ferrand, France.
  • Olié E; Fondation FondaMental, Créteil, France; IGF, Univ. Montpellier, CNRS, INSERM, Department of Emergency Psychiatry and Acute Care, CHU Montpellier, Montpellier, France.
  • Polosan M; Fondation FondaMental, Créteil, France; Univ. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.
  • Samalin L; Fondation FondaMental, Créteil, France; Department of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), Clermont-Ferrand, France.
  • Schwan R; Université de Lorraine, Centre Psychothérapique de Nancy, Inserm U1254, Nancy, France.
  • Roux P; Fondation FondaMental, Créteil, France; Centre Hospitalier de Versailles, Service Universitaire de Psychiatrie d'Adulte et d'Addictologie, Le Chesnay, France; Université Paris-Saclay & Université Versailles Saint-Quentin-En-Yvelines, INSERM UMR1018, Centre de recherche en Épidémiologie et Santé
  • Barau C; Plateforme de Ressources Biologiques, HU Henri Mondor, Créteil, France.
  • Richard JR; INSERM U955 IMRB, Translational Neuropsychiatry laboratory, AP-HP, Hôpital Henri Mondor, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Paris Est Créteil University (UPEC), ECNP Immuno-NeuroPsychiatry Network.
  • Tamouza R; INSERM U955 IMRB, Translational Neuropsychiatry laboratory, AP-HP, Hôpital Henri Mondor, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Paris Est Créteil University (UPEC), ECNP Immuno-NeuroPsychiatry Network; Fondation FondaMental, Créteil, Franc
  • Leboyer M; INSERM U955 IMRB, Translational Neuropsychiatry laboratory, AP-HP, Hôpital Henri Mondor, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Paris Est Créteil University (UPEC), ECNP Immuno-NeuroPsychiatry Network; Fondation FondaMental, Créteil, Franc
  • Andreazza AC; Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Mitochondrial Innovation Initiative, MITO2i, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Psychiatry Res ; 339: 116063, 2024 Sep.
Article em En | MEDLINE | ID: mdl-39003800
ABSTRACT
The object of this study is test whether mitochondrial blood-based biomarkers are associated with markers of metabolic syndrome in bipolar disorder, hypothesizing higher lactate but unchanged cell-free circulating mitochondrial DNA levels in bipolar disorder patients with metabolic syndrome. In a cohort study, primary testing from the FondaMental Advanced Centers of Expertise for bipolar disorder (FACE-BD) was conducted, including 837 stable bipolar disorder patients. The I-GIVE validation cohort consists of 237

participants:

stable and acute bipolar patients, non-psychiatric controls, and acute schizophrenia patients. Multivariable regression analyses show significant lactate association with triglycerides, fasting glucose and systolic and diastolic blood pressure. Significantly higher levels of lactate were associated with presence of metabolic syndrome after adjusting for potential confounding factors. Mitochondrial-targeted metabolomics identified distinct metabolite profiles in patients with lactate presence and metabolic syndrome, differing from those without lactate changes but with metabolic syndrome. Circulating cell-free mitochondrial DNA was not associated with metabolic syndrome. This thorough analysis mitochondrial biomarkers indicate the associations with lactate and metabolic syndrome, while showing the mitochondrial metabolites can further stratify metabolic profiles in patients with BD. This study is relevant to improve the identification and stratification of bipolar patients with metabolic syndrome and provide potential personalized-therapeutic opportunities.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno Bipolar / DNA Mitocondrial / Biomarcadores / Ácido Láctico / Síndrome Metabólica Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno Bipolar / DNA Mitocondrial / Biomarcadores / Ácido Láctico / Síndrome Metabólica Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article